@article{10902/31026,
year = {2023},
url = {https://hdl.handle.net/10902/31026},
abstract = {Epstein-Barr virus-positive (EBV+) post-transplant lymphoproliferative disease (PTLD) is an ultra-rare and aggressive condition that may occur following allogeneic hematopoietic cell transplant (HCT) due to immunosuppression. Approximately half of EBV+ PTLD cases are relapsed or refractory (R/R) to initial rituximab-containing therapy. There are limited treatment options and no standard of care for patients with R/R EBV+ PTLD, and little is known about their treatment history and outcomes. We performed a multinational, multicenter, retrospective chart review of patients with R/R EBV+ PTLD following HCT to describe patients' demographic and disease characteristics, treatment history, and overall survival (OS) from rituximab failure. Among 81 patients who received initial treatment with rituximab as monotherapy (84.0%) or in combination with chemotherapy (16.0%), median time from HCT to PTLD diagnosis was 3.0 months and median OS was 0.7 months. Thirty-six patients received a subsequent line of treatment. The most frequent causes of death were PTLD (56.8%), graft-versus-host disease (13.5%) and treatment-related mortality (10.8%). In multivariate analysis, early PTLD onset and lack of response to initial treatment were associated with mortality. This real-world study demonstrates that the prognosis of patients with R/R EBV+ PTLD following HCT remains poor, highlighting the urgent unmet medical need in this population.},
organization = {ACKNOWLEDGEMENTS. The authors gratefully acknowledge Benedetto Bruno, Federica Cavallo, Paul Chauvet, Sylvain Choquet, Vikas Dharnidharka, Daan Dierickx, Ulrich Jaeger, Charles Herbaux, Howard Huang, Periana Minga, Pietro Merli, Anthea Peters, Loretta Nastoupil, Josea
Pérez Simón, John Reitan, Guillermo Rodríguez, Montserrat Rovira, Ahmed Sawas, Francesca Sismondi, Erin Sundaram, Ralph Ulrich Trappe, Jamie Wenke, and Heiner Zimmermann for their assistance with manuscript development. This study was funded by Atara Biotherapeutics. Medical writing assistance was provided by Folabomi Oladosu PhD, and Lee Blackburn MSc, from AMICULUM USA, funded by Atara Biotherapeutics.},
publisher = {Nature Publishing Group},
publisher = {Bone Marrow Transplantation, 2023},
title = {Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy},
author = {Socié, Gérard and Barba, Pere and Barlev, Arie and Sanz, Jaime and García-Cadenas, Irene and Chevallier, Patrice and Fagioli, Franca and Guzmán-Becerra, Norma and Kumar , Deepali and Ljungman, Per and Pigneux, Arnaud and Sadetsky, Natalia and Yáñez San Segundo, Lucrecia and Shadman, Mazyar and Storek, Jan and Thirumalai, Dhanalakshmi and Xing, Baodong and Mothy, Mohamed},
}